Nippon Chemiphar and Zeria Pharmaceutical have launched a non-steroidal anti-inflammatory drug, zaltoprofen, under the brand names Soleton Tab 80 and Peon Tab 80, respectively. The product is claimed to have few gastrointestinal side effects. The Japanese market for NSAIDs is estimated at 120 billion yen ($1.13 billion; 1992 figures), and the companies say they are aiming for peak sales in the region of 20 billion yen.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze